Introduction
============

Psoriasis vulgaris, an immunologically mediated skin disease, is a common disorder, having as main pathogenetic mechanisms the chronic inflammation and keratinocytes hyperproliferation \[[@b1-cm-89-11]\]. The keratinocytes differentiation is altered and the expression of genes in the psoriasis plaque may also be affected \[[@b2-cm-89-11]\]. The antimicrobial peptides and proteins production during the innate and adaptive immune response reflect the genetic susceptibility to psoriasis \[[@b3-cm-89-11]\].

Psoriasis vulgaris is not a life threatening disease, but it affects severly the quality of life; there is still no causative treatment \[[@b4-cm-89-11]\].

Due to the psoriasis chronicity and the absence of a curative treatment \[[@b5-cm-89-11]\], the disease prevalence remains a question \[[@b6-cm-89-11]\]: it was estimated to more than 3% in the United States and Canada \[[@b7-cm-89-11]\] and between 0.6 to 6.5% in Europe \[[@b8-cm-89-11]\].

The onset of psoriasis vulgaris may be at any age, but two peaks were observed, around 20--30 and over 50 years of age \[[@b9-cm-89-11]\]; pediatric psoriasis can reach about 30% of all cases \[[@b10-cm-89-11]\]. The early onset of chronic plaque psoriasis in white population was associated with 36 genetic loci \[[@b11-cm-89-11]\], a finding which supports the assumption that the age of onset is, at least partially, genetically determined \[[@b12-cm-89-11]\].

Triggering factors of psoriasis
-------------------------------

Psoriasis can be precipitated by multiple factors, exogenous or endogenous.

Among the exogenous triggers there are physical factors (friction, injury, injection site, surgical scar, pressure points, scalding, burning, ultraviolet or X radiation), seasonal variations \[[@b13-cm-89-11]\], chemical factors (cauterization, chronic alkaline damage, toxic agents) \[[@b13-cm-89-11],[@b14-cm-89-11]\]. Other exogenous precipitating factors can be alcohol consumption \[[@b15-cm-89-11],[@b16-cm-89-11]\], smoking \[[@b5-cm-89-11]\], drugs (gold salts \[[@b17-cm-89-11]\], lithium, antihypertensives -- beta-blockers, antimalarials, antifungals, which have all a strong causal relationship and can trigger or worsen the psoriatic clinical phenomena \[[@b18-cm-89-11],[@b19-cm-89-11],[@b20-cm-89-11]\]; even diet can precipitate symptoms \[[@b5-cm-89-11]\].

Infections with one of the following agents can trigger or exacerbate psoriasis: Streptococcus Beta Haemolyticus \[[@b21-cm-89-11]\], Streptococcus pyogenes \[[@b22-cm-89-11]\], Hepatitis C virus \[[@b23-cm-89-11],[@b24-cm-89-11]\], Varicella zoster virus \[[@b25-cm-89-11]\], herpes simplex virus \[[@b26-cm-89-11]\], Human immunodeficiency virus \[[@b27-cm-89-11]\], Candida albicans \[[@b28-cm-89-11]\], upper respiratory pathogens \[[@b29-cm-89-11]\].

Other risk factors for psoriasis onset are skin injuries, in the context of Köbner phenomenon \[[@b30-cm-89-11],[@b31-cm-89-11]\].

The endogenous factors are also triggers for psoriasis. Here can be mentioned the allergies \[[@b32-cm-89-11],[@b33-cm-89-11]\] and hormonal changes \[[@b5-cm-89-11]\], but the most common trigger for several inflammatory skin diseases, including psoriasis, is the emotional stress \[[@b34-cm-89-11],[@b35-cm-89-11]\].

Skin: hormones target and synthesis organ
-----------------------------------------

The skin, the central nervous system and the endocrine system have a common embryological origin and they all express the same, numerous mediators \[[@b36-cm-89-11]\]. For example, human skin produces, activates or inactivates neuropeptides like serotonin \[[@b37-cm-89-11]\]; some opioid peptides and their receptors are also expressed in the skin \[[@b38-cm-89-11]\].

The normal skin development and function is influenced by hormones: for example, the growth hormone stimulates keratinocyte proliferation \[[@b39-cm-89-11]\], and thyroid hormones act directly on hair follicles \[[@b40-cm-89-11]\]. The skin is a neuroendocrine organ, capable of hormone synthesis and release \[[@b41-cm-89-11]\]: corticosteroids and sex hormones are synthesized and transformed \[[@b42-cm-89-11]\] (with sebocytes playing a central role in cutaneous androgen metabolism \[[@b43-cm-89-11]\]); catecholamines are synthesized by keratinocytes and melanocytes \[[@b36-cm-89-11]\].

Dermal fibroblasts present strong circadian rhythm \[[@b44-cm-89-11]\] and melatonin is implicated in the regulation of hair growth cycle \[[@b45-cm-89-11]\] and is metabolized \[[@b46-cm-89-11]\]. Prolactin is also implicated in hair growth regulation, and scalp skin and hair follicles are sources of prolactin \[[@b47-cm-89-11]\].

The cutaneous endocrine system is highly important in multiple systemic diseases \[[@b48-cm-89-11]\].

Conditions associated with psoriasis
------------------------------------

A large spectrum of diseases with hormonal involvement are associated with psoriasis: depression \[[@b49-cm-89-11]\], arterial hypertension \[[@b50-cm-89-11]\] and other cardiovascular disorders: atherothrombotic disease or transient ischemic attack \[[@b51-cm-89-11]\], nonalcoholic steatohepatitis \[[@b52-cm-89-11]\], chronic inflammatory bowel disease \[[@b53-cm-89-11]\] and Crohn's disease \[[@b54-cm-89-11]\], dyslipidemia, obesity, metabolic syndrome \[[@b55-cm-89-11]\], insulin resistance \[[@b56-cm-89-11]\] and diabetes mellitus, respiratory diseases, including asthma \[[@b57-cm-89-11]\], chronic kidney disease \[[@b58-cm-89-11]\], uveitis \[[@b54-cm-89-11]\], malignant lymphoma \[[@b55-cm-89-11]\]. The treatment of those associated diseases might aggravate psoriasis \[[@b57-cm-89-11]\].

The role of hormones in psoriasis
---------------------------------

The hormones also have an important influence on the severity of psoriasis clinical manifestations. This fact is indicated by the disease frequency peaks during puberty \[[@b59-cm-89-11]\] and menopause \[[@b60-cm-89-11]\], besides the peaks around the age of 30 and 50 years \[[@b61-cm-89-11]\]. Therefore, the hormonal variances, major changes and the hormonal diseases could represent risk, triggering or modulating factors in the evolution of psoriasis.

### 1. Sex hormones and psoriasis

Psoriasis is a chronic inflammatory disease, characterized mainly by the involvement of Th1 type of T lymphocytes \[[@b62-cm-89-11]\], and also by neutrophils, dendritic cells, and mast cells, all major inflammatory cytokines producers: interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and *interleukins (*IL-2, IL-12, IL-17 and IL-23) \[[@b63-cm-89-11],[@b64-cm-89-11]\].

Estrogens influence the immune responses, modulating the development and activation of immune cells, through the influence and control exerted upon the expression of different cytokines \[[@b65-cm-89-11]\].

*In vitro* and *in vivo* studies demonstrated the anti-inflammatory effects of estrogens: they decrease the neutrophil's blood level and keratinocytes production of some macrophage-attracting cytokines \[[@b66-cm-89-11]\], and they increase the production of IL-10 by B lymphocytes and dendritic cells \[[@b67-cm-89-11]\]. Those estrogens effects may also decrease the psoriatic inflammation. Other effect of estrogens is the decreasing of matrix metalloproteinase activity in fibroblasts \[[@b66-cm-89-11]\], which lowers the destruction of extracellular matrix and the release of growth factors, another pathogenic psoriatic link.

The effects of estrogen are differently mediated by estrogens receptor-α (ER-α) and β (ER-β) \[[@b68-cm-89-11],[@b69-cm-89-11],[@b70-cm-89-11]\] ([Figure 1](#f1-cm-89-11){ref-type="fig"}). Among negative effects of estrogens in psoriasis, some should be mentioned: the suppression of apoptosis and the stimulation of proliferation at keratinocyte level, the stimulation of growth factors production in macrophages, keratinocytes and fibroblasts \[[@b66-cm-89-11]\], which can stimulate the development of neovascularization, a pathogenic way in psoriasis \[[@b71-cm-89-11]\].

At the same time, Progesterone, which is a commonly indicated drug, can precipitate some forms of psoriasis (pustular) \[[@b20-cm-89-11]\].

#### 1.1. Pregnancy

Extremely high levels of hormonal and immunological changes occur during pregnancy, as maternal adaptations to the developing fetus.

The evolution of psoriasis is variable during pregnancy \[[@b72-cm-89-11]\]. At mid pregnancy (around 30^th^ week of gestation), the patients' psoriatic symptoms can diminish (in \>50%) or worsening (in \>20%) \[[@b73-cm-89-11]\]. A possible explanation could be that at this moment, there is an immunity shift from Th2 to Th1, mainly due to the increased levels of estrogen, progesterone and cortisol \[[@b74-cm-89-11]\].

Other chronic immune diseases Th1-driven were shown to improve during pregnancy, such as multiple sclerosis \[[@b75-cm-89-11]\] and rheumatoid arthritis \[[@b76-cm-89-11]\]. Therefore, it was supposed that the increased hormone levels improve the psoriatic symptoms \[[@b77-cm-89-11]\].

Due to the decrease in hormonal levels after parturition and during menopause, the psoriasis severity seems to accentuate \[[@b63-cm-89-11]\]. In these conditions, it was assumed that the flares occurring in the postpartum period represent rather a return to the initial level than a true worsening \[[@b73-cm-89-11]\].

A moderate or severe form of psoriasis can increase the risk for a poor outcome in pregnancy \[[@b78-cm-89-11]\], abortions, eclampsia, premature rupture of membranes, or macrosomia \[[@b79-cm-89-11]\], but this can be due to the multiple comorbidities associated with psoriasis, which can represent risk factors in pregnancy.

Definitely, psoriasis does not represent a contraindication for a pregnancy \[[@b77-cm-89-11]\]. If a systemic treatment is necessary, mothers are told not to nurse because the drugs may be excreted in milk \[[@b80-cm-89-11]\].

#### 1.2. Menopause

During menopause, the estrogen level decline and a low-grade inflammation may appear \[[@b81-cm-89-11]\], meaning that menopause may aggravate the psoriasis evolution \[[@b82-cm-89-11]\]. This fact is in concordance with the observation that after menopause the incidence of chronic inflammatory diseases in women became closer or higher than the incidence in males \[[@b83-cm-89-11]\].

#### 1.3. Androgens

The epidermis, dermis and hair follicle and the associated sebaceous glands express androgen receptors, and the skin is an important androgen target \[[@b84-cm-89-11]\]. Androgen hormones influence the homeostasis of the epidermal barrier, the growth and differentiation of the hair and the sebaceous gland \[[@b85-cm-89-11]\]. They also antagonize the macrophage's production of *vascular endothelial growth factor* (VEGF), which can prolong the inflammation and the wound healing \[[@b69-cm-89-11]\]. The adrenal androgens decrease in chronic inflammatory diseases \[[@b86-cm-89-11]\] and the therapies based on androgen can aggravate/exacerbate psoriasis \[[@b87-cm-89-11]\].

### 2. Stress hormones and exercise

Endocrine and immune reactions are both highly influenced by stress. At the same time, the evolution is marked by the important stressful moments in life \[[@b63-cm-89-11]\]. The hypothalamic-pituitary-suprarenal axis controls the stress hormones, cortisol and epinephrine, which are antagonists and have important effects on immune system.

Immune cells (macrophages, lymphocytes T and B) express beta-adrenergic receptor \[[@b88-cm-89-11]\] and epinephrine induces multiple but dual immune responses: promotes macrophages responses through increasing secretion of cytokines TNF-α, IL-1, IL-10 \[[@b89-cm-89-11]\], and regulates the level of T and B lymphocyte function. Also, it has bee observed that an acute activation of the sympathetic nervous system attenuates the innate immune response \[[@b90-cm-89-11]\].

The immunomodulation in stress takes place through intersections in signaling cascade at different levels: for example, stress signals in immune response are regulated through the key Nuclear Factor-kappaB (NF-κB) and the epinephrine stimulation of β2-adrenergic receptors, expressed on immune cells, intersect with the NF-κB signaling cascade \[[@b91-cm-89-11]\] ([Figure 2](#f2-cm-89-11){ref-type="fig"}).

Glucocorticoids prevent the inflammatory changes by inhibiting the migration of leukocytes and suppressing T cells \[[@b92-cm-89-11]\]. The stimulation of epinephrine and adrenergic receptors may also exert some corticosteroid effects \[[@b93-cm-89-11]\].

The cortisol response to stress is diminished in psoriasis \[[@b94-cm-89-11]\]. The psoriatic patients present higher levels of epinephrine and adrenocorticotropic hormone and lower levels of cortisol and corticotrophin releasing factor \[[@b95-cm-89-11]\]. Epinephrine can modulate the remission phase and cortisol the eruption phase \[[@b22-cm-89-11]\].

The stress link in psoriasis is sustained also by the fact that a regular physical activity may have favorable effect on psoriasis evolution. Through metabolic and psycho-neuro-immune effects, a regular exercise influences positively the metabolic comorbidities, lowers the risk and the onset of psoriasis \[[@b53-cm-89-11]\].

### 3. Prolactin

Prolactin (PRL) is the pituitary hormone of lactation and reproduction. The epidermal keratinocytes express receptors for prolactin \[[@b96-cm-89-11]\] and the hormone has proliferative effects on keratinocytes \[[@b97-cm-89-11]\], epithelial cells, and lymphocytes \[[@b98-cm-89-11]\].

There is a true "PRL--skin connection" \[[@b99-cm-89-11]\]. PRL exerts a variety of immunostimulative effects which may promote the development of psoriasis \[[@b100-cm-89-11]\]: it enhances keratinocytes chemokine production (IL-17) and favors infiltration with Th lymphocytes \[[@b96-cm-89-11],[@b101-cm-89-11]\], stimulates IFN-γ production and promotes angiogenesis \[[@b102-cm-89-11]\], regulates the maturation of T cells \[[@b103-cm-89-11]\]. According to those multiple immune roles, hyperprolactinemia was observed in several autoimmune diseases (lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, Hashimoto's thyroiditis, multiple sclerosis) \[[@b104-cm-89-11]\].

PRL is involved in the psoriasis etiopathogenesis \[[@b105-cm-89-11]\] and this role of prolactin is sustained by the observations that psoriasis can be aggravated during the development of prolactinoma \[[@b106-cm-89-11]\]. A significant decrease in prolactin level in patients with psoriasis was noticed after systemic treatment \[[@b98-cm-89-11]\]. Several studies have shown a positive relation between serum prolactin levels and psoriasis severity \[[@b107-cm-89-11],[@b108-cm-89-11],[@b109-cm-89-11]\]. Bromocriptine, used in prolactinoma, may be useful in the psoriasis treatment \[[@b108-cm-89-11]\].

### 4. Thyroid hormones

The thyroid hormones present receptors expressed in the skin and they are important factors that can stimulate skin proliferation \[[@b110-cm-89-11]\], by increasing the level of epidermal growth factor \[[@b111-cm-89-11]\].

Arguments for the aggravating effect of thyroid hormones in psoriasis are the following: the psoriasis can be intensified by an excessive production of thyroid hormones \[[@b112-cm-89-11]\], the free thyroxine is increased significantly in the psoriatic patients \[[@b113-cm-89-11]\], in severe psoriasis, there are increased levels of *thyroid-stimulating hormone* \[[@b111-cm-89-11]\], and the patients with thyroiditis had longer disease periods \[[@b113-cm-89-11]\].

Also, it has been shown that the antithyroid drugs have an anti-proliferative effect on psoriasis \[[@b112-cm-89-11]\]. For example, propylthiouracil, exhibits antiproliferative and immunomodulatory effects and is beneficial in psoriasis \[[@b114-cm-89-11]\]. There were reported cases of psoriasis resolution after thyroidectomy \[[@b115-cm-89-11],[@b116-cm-89-11]\].

### 5. Leptin, ghrelin, insulin & obesity

The metabolic syndrome, including obesity and diabetes mellitus, are strongly associated with psoriasis \[[@b57-cm-89-11]\].

Leptin is an adipose cell hormone with long-term action that decreases the appetite and suppresses food intake. Ghrelin is released primarily in the stomach and is a fast-acting hormone, increasing the appetite and playing a role in meal initiation \[[@b117-cm-89-11]\].

Ghrelin can antagonize the insulin system \[[@b118-cm-89-11]\] and there is a negative correlation between severity of psoriasis and ghrelin level \[[@b119-cm-89-11]\].

Also, there is a relationship between leptin, obesity and psoriasis. But there are contradictive reports regarding the leptin levels in psoriasis, significantly decreased \[[@b120-cm-89-11]\] or higher \[[@b121-cm-89-11]\]. But, an argument for the leptin molecular link between psoriasis and metabolic comorbidities is represented by the higher serum levels of leptin in overweight or obese psoriatic patients \[[@b122-cm-89-11]\].

Strongly associated with insulin resistance are both psoriasis \[[@b123-cm-89-11]\] and obesity \[[@b124-cm-89-11]\]. In both, there are also common pro-inflammatory pathways involved (TNF-α, IL-6). Reducing the obesity chronic low-level inflammation may improve insulin sensitivity and leptin levels \[[@b125-cm-89-11]\].

Conclusions
===========

Even though the sex hormones and prolactin are the most implicated in psoriasis pathogenesis and clinical manifestations, there are a lot of other hormonal mechanisms with significant influence on the evolution of psoriasis, therefore new therapeutic ways need to be explored.

At the same time, a hormonal assessment should be performed in patients with psoriasis, in order to correctly diagnose and treat pathologies that may be related with psoriasis exacerbations.

Due to the pathogenic complexity, there a curative treatment for psoriasis is still missing and hormonal therapeutic interventions may relieve the clinical phenomena in psoriasis.
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